// App-Quantinova.ai

TPS9 : JAVELIN ovarian PARP 100 study design: Phase III trial of avelumab + chemotherapy followed by avelumab + talazoparib maintenance in previously untreated epithelial ovarian cancer.

Researchers

Presenter

  • Ramez Nassef Eskander

Principal Investigators

  • Jonathan A. Ledermann

  • Michael J. Birrer

  • Keiichi Fujiwara

  • Stephanie Gaillard

  • Gary Edward Richardson

  • Caimiao Wei

  • Mahadi Ali Baig

  • Fabian Zohren

  • Bradley J. Monk

Medical Centers

  • UC San Diego Moores Cancer Center, San Diego, CA

  • University College London Hospitals/UCL Cancer Institute, London, United Kingdom

  • Center for Systems Biology, Boston, MA

  • Department of Orthopaedic Oncology and Surgery, Saitama Medical University International Medical Center, Hidaka, Japan

  • Departments of Oncology and Gynecology and Obstetrics, Johns Hopkins Medical Institutions, Baltimore, MD

  • Oncology Clinics Victoria, Brighton Vic, Australia

  • Oncology, Pfizer, Groton, CT

  • Oncology, Pfizer, New York, NY

  • Oncology, Pfizer, Cambridge, MA

  • Arizona Oncology (US Oncology Network), Tempe, AZ

Locations

  • United States

  • United Kingdom

  • Japan

  • Australia

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Genetic Disorder

Disease

  • Ovarian cancer

  • Peritoneal cancer

  • Gynaecological cancer

Biomarkers

  • Breast cancer type 1 susceptibility protein

Drug/Treatment

  • Bevacizumab

  • Carboplatin

  • Talazoparib

  • Paclitaxel

  • Avelumab

Outcome

  • N/A

Study Design

  • Randomized

  • Double Blind/Blinded

  • Open Label

  • Multicenteric

Phase

  • III

Study Id's

  • NCT03642132

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved